Bosutinib induced a potent and dose-related inhibition of COL1A2, COL3A1, FN1 and CTGF expression in SSc dermal fibroblasts and potent inhibition of total collagen production by these cells. The gene discussed is CCN2; the disease is systemic sclerosis.